Skip to main content
Clinical Trials/NCT02226601
NCT02226601
Unknown
Not Applicable

Aprepitant to Mitigate Opioids' Cognitive Side Effects

University of Arizona1 site in 1 country50 target enrollmentOctober 2014

Overview

Phase
Not Applicable
Intervention
Aprepitant
Conditions
Cognitive Dysfunction
Sponsor
University of Arizona
Enrollment
50
Locations
1
Primary Endpoint
cognitive function
Last Updated
10 years ago

Overview

Brief Summary

Morphine and similar substances (called opioids) are often prescribed for moderate to severe pain, such as after a surgery, thus allowing for minimal pain and a better recovery. Unfortunately various, non-dangerous side effects from opioids occur often that limit the way patients feel and can take of themselves, despite otherwise good pain control and minimal limitations from the surgery itself.

Detailed Description

In this proposed study the investigators want to examine if the drug aprepitant can decrease the so called "cognitive impairments" opioids may cause, such as drowsiness, loopiness and feeling "high". This would allow for a better recovery period, in which patients can be more "themselves", participate in activities around them and move forward. Subjects scheduled for elective surgeries with expected opioid medication for moderate to severe pain and good functional status shortly after surgery will be randomized to receive either aprepitant or placebo shortly before their surgery and for two more days thereafter. A telephone interview for cognitive status and several specific questions will be used to assess the effect of aprepitant on the subjects' cognitive and functional status.

Registry
clinicaltrials.gov
Start Date
October 2014
End Date
October 2016
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Kai Schoenhage

Assistant Professor

University of Arizona

Eligibility Criteria

Inclusion Criteria

  • healthy English speaking, opioid-naive consenting adults

Exclusion Criteria

  • current or very recent (\< 3 months) opioid therapy
  • morbid obesity
  • liver disease
  • therapy with pimozide, terfenadine, astemizole, cisapride, vitamin K antagonists (warfarin), hormonal contraceptives
  • acute or chronic infections
  • immunocompromised status
  • hemodynamically unstable, hemorrhage (bleeding)
  • recent surgery
  • pregnancy, nursing
  • younger than 18 years old

Arms & Interventions

Aprepitant

Aprepitant * 40 mg IV pre-operatively * 40 mg PO post-op day #1 * 40 mg PO post-op day #2

Intervention: Aprepitant

Placebo

* electrolyte (0.9% NaCl) infusion) pre-operatively * capsule without medication on post-op day #1 * capsule without medication on post-op day #2

Intervention: Placebo

Outcomes

Primary Outcomes

cognitive function

Time Frame: 3 days post-operatively

questionnaires

Study Sites (1)

Loading locations...

Similar Trials